GlaxoSmithKline’s chief executive Dame Emma Walmsley is under increasing pressure from investors to prove her strategy for the business will pay off in the next few years.
Walmsley took the helm in 2017, and the spin-off of its consumer health division (a joint venture with Pfizer) is...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
